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Abstract : Factors contributing to mortality in healthcare-associated pneumonia 
（HCAP） have not been investigated fully.  We reviewed the etiology and identied 
prognostic factors of HCAP in hospitalized patients.  We conducted a retrospective 
study of 500 Japanese patients with HCAP to assess these factors, with special 
emphasis on microbial etiology.  Patients with HCAP were older （73.4 ± 11.4 
years）, more predominantly male （74.4％）, and had more smoking history and 
comorbidity than did community-acquired pneumonia （CAP） patients.  Microbes 
were identied in 52.8％ of HCAP patients.  The most frequent causative microbial 
agents were Streptococcus pneumoniae （n＝108, 21.6％）, influenza virus （n＝
47, 9.4％）, and Pseudomonas aeruginosa （n＝40, 8.0％）.  Multiple drug-resistant 
（MDR） pathogens were more frequent in HCAP patients （9.8％） than CAP 
patients. Overall, 47 HCAP patients （9.4％） died, with mortality being higher in 
HCAP than CAP patients.  The three leading causes of non-survival from HCAP 
were S. pneumoniae, inuenza virus, and P. aeruginosa.  MDR pathogens accounted 
for 21.3％ of non-survivors.  Multivariate analysis revealed disease severity on 
admission and treatment failure of initial antibiotics as independent factors for 
30-day mortality.  Among patients with treatment failure of initial antibiotics, 29.9％ 
had received appropriate antibiotics.  The most frequent pathogens in HCAP 
were S. pneumoniae, inuenza virus, and P. aeruginosa, in both survivors and non-
survivors.  Disease severity on admission and treatment failure of initial antibiotics 
were independent factors for mortality.  MDR pathogens are important therapeutic 
targets to mitigate negative results, and treatment strategies other than antibiotic 
selection are also required.
Key words : healthcare-associated pneumonia, etiology, mortality, prognostic factors, 
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Introduction
　The 2005 guidelines of the American Thoracic Society / Infectious Diseases Society of America 
（ATS / IDSA） established the concept of healthcare-associated pneumonia （HCAP）, describing 
a patient population with frequent healthcare contacts and therefore at high risk of contracting 
resistant organisms 1）.  Data supporting the HCAP concept were derived from a retrospective 
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2-year （2002-2003） cohort analysis of 4543 patients with pneumonia hospitalized in the United 
States2）, and many patients had multiple drug-resistant （MDR） pathogen infections.  However, in 
recent studies evaluating the etiology in patients with HCAP, the incidence of MDR pathogens 
was far lower than that reported in the previous study 2）.
　HCAP patients are older and have a higher frequency of comorbidity 2-4） than patients with 
community-acquired pneumonia （CAP）, and chronic conditions in older adults are known to 
increase the risk of inuenza complications.  Thus, we assumed that inuenza virus infection is 
not uncommon in HCAP ; however, few studies have investigated the frequency of influenza 
virus infection in this condition.  Thus, the aims of this study were to review the microbial etiol-
ogy and frequency of inuenza virus infection in HCAP and to identify factors contributing to 
mortality in patients with this disease.
Materials and methods
　We performed a retrospective study of all patients hospitalized with HCAP at our institution 
in Saitama, Japan, from January 2002 to December 2011.  Characteristics of HCAP patients were 
compared with those of CAP patients hospitalized in our institution during the same period 5）. 
The study protocol was approved by the Ethics Committee of the Saitama Cardiovascular and 
Respiratory Center （2011027）.  Pneumonia was diagnosed on the basis of symptoms suggestive 
of lower respiratory tract infection and the development of inltration on chest X-ray.  HCAP 
was defined when the criteria of the ATS / IDSA guidelines 1） were satisfied （Table 1）, and 
severe HCAP was defined when at least one major criterion or three minor criteria of the 
IDSA / ATS guidelines 6） were present.  Patients with acquired immunodeficiency syndrome, 
tuberculosis, non-resected lung cancer, or a conrmed alternative diagnosis at the end of follow-
up were excluded from the study.
　Diagnosis of causative microorganisms was based on the results of semiquantitative cultures 
of respiratory samples or blood, paired sera, urinary antigen tests for Streptococcus pneumoniae 
and Legionella pneumophila, and nasopharyngeal swabs for influenza virus as reported previ-
ously 5）.  In this study, MDR pathogens included methicillin-resistant Staphylococcus aureus 
（MRSA）, Pseudomonas aeruginosa, Acinetobacter baumannii, Stenotrophomonas maltophilia, and 
Table 1.　Number of patients in each ATS / IDSA 2005 HCAP category 1）
Category n ％
Hospitalization for 2 days or more in the preceding 90 days 95 19.0
Resided in a nursing home or long-term care facility 34 6.8
Received recent intravenous antibiotic therapy, chemotherapy, or wound care within the past 30 days 
of the current infection
99 19.8
Attended a hospital or hemodialysis clinic 429 85.8
ATS, American Thoracic Society; HCAP, healthcare-associated pneumonia; IDSA, Infectious Diseases Society of 
America.
Numbers and percentages add up to＞ 500 and＞ 100％ because some patients have more than 1 risk factor.
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extended-spectrum β-lactamase-producing Enterobacteriaceae, based on previous reports showing 
problematic clinical outcomes for infections caused by these pathogens1, 7）.
　Treatment prescribed during the rst 24 h of hospitalization was considered the initial treat-
ment.  Concordant CAP therapy was dened according to established IDSA / ATS guidelines 6）. 
The treatment effect of initial antibiotics after admission was judged after the rst 48～72 h of 
therapy, based on body temperature, arterial oxygen saturation measured with pulse oximeter 
（SpO2） or arterial partial pressure of oxygen, and white blood cell count 8）.  In cases of treat-
ment failure, the appropriateness of administered antibiotics was judged by the in vitro suscepti-
bility of cultured bacteria and coverage of atypical pathogens and inuenza virus.
　Variables assessed as possible risk factors for 30-day mortality of HCAP included : patient 
demographic factors, the presence of the comorbid diseases listed in Table 2, the presence of 
prior antibiotics administered by a local physician, causative pathogens, disease severity on admis-
sion, and initial treatment antibiotics.
Statistical analysis
　Results are presented as the number and percentage or mean±standard deviation unless 
otherwise indicated.  Risk factors for mortality from HCAP were evaluated by univariate and 
multivariate logistic regression analysis.  Variables showing signicance by univariate analysis were 
included in the multivariate logistic regression analysis with backward elimination method.  The 
95％ condence interval （CI） for all comparisons is also reported.  In all instances, a 2-tailed 
P value of＜ 0.05 was considered to indicate statistical signicance.  All statistical analyses were 
performed with Statistical Analysis System software （SAS version 9.1.3 ; SAS Institute, Inc., Cary, 
NC）.
Results
　Overall, 500 patients were enrolled during the study period.  Characteristics of the patients 
diagnosed as having HCAP are shown in Table 2.  Patients with HCAP were older, more pre-
dominantly male, had more smoking history, more comorbidity, and had more frequently received 
long-term oxygen therapy and antibiotics prior to admission to our hospital than did patients 
with CAP.
Microbiological patterns
　Diagnostic methods used and results obtained （positive cases / number tested） are listed in 
Table 3.  The etiologic microorganisms of HCAP are shown in Table 4.  Of the 264 patients 
（52.8％） with a pathogen identified, 40 had two or three pathogens.  S. pneumoniae was the 
most frequent microorganism found in polymicrobial infections, with S. pneumoniae and inuenza 
virus being the most frequent combination （Table 4）.  Of the 47 patients with inuenza virus 
infection, 30 （63.8％） were diagnosed by positive rapid infuluenza diagnostic test （RIDTs）, 10 
（21.3％） were diagnosed by serology, and 7 （14.9％） were positive for both RIDT and serology. 
Eighteen of the 47 patients （38.3％） with inuenza virus infection had polymicrobial infections 
Takashi ISHIGURO, et al266
Table 2.　Characteristics of patients with HCAP and CAP
Factor CAP HCAP P-value
Patients 1032 500 －
Sex（male） 683 （66.2％） 372 （74.4％） 0.001
Age＊ 64.0 ± 18.3 73.4 ± 11.4 ＜0.001
Smoking habit 604 （58.5％） 342 （68.4％） ＜0.001
Prior antibiotics, no 628 （60.9％） 348 （69.6％） ＜0.001
Long-term oxygen therapy 23 （2.2％） 131 （26.2％） ＜0.001
Comorbidity
　No 295 （28.6％） 35 （7.0％） ＜0.001
　Respiratory disease alone 268 （26.0％） 183 （36.6％）
　Systemic disease alone 274 （26.6％） 119 （23.8％）
　Both 195 （18.9％） 163 （32.6％）
Respiratory diseases
　Chronic obstructive pulmonary disease 166 （16.1％） 164 （32.8％） ＜0.001
　Asthma 102 （9.9％） 48 （9.6％） 0.93
　Bronchiectasis 55 （5.3％） 40 （8.0％） 0.05
　Nontuberculous mycobacteria 36 （3.5％） 31 （6.2％） 0.02
　Old pulmonary tuberculosis 54 （5.2％） 52 （10.4％） ＜0.001
　Chronic pulmonary aspergillosis 15 （1.5％） 10 （2.0％） 0.52
　Interstitial pneumonia 43 （4.2％） 56 （11.2％） ＜0.001
　Post lung cancer operation 35 （3.4％） 23 （4.6％） 0.26
　Pneumoconiosis 7 （0.7％） 7 （1.4％） 0.25
　Pulmonary thromboembolism 4 （0.4％） 2 （0.4％） 1.00
　Chronic empyema 4 （0.4％） 5 （1.0％） 0.16
　Others 17 （1.6％） 13 （2.6％） 0.24
Systemic diseases
　Hypertension 114 （11.0％） 45 （9.0％） 0.25
　Congestive heart failure 35 （3.4％） 40 （8.0％） ＜0.001
　Ischemic heart disease 33 （3.2％） 38 （7.6％） ＜0.001
　Diabetes mellitus 107 （10.4％） 63 （12.6％） 0.19
　Valvular heart disease 10 （1.0％） 16 （3.2％） 0.003
　Arrhythmia 42 （4.1％） 37 （7.4％） 0.009
　Cerebrovascular disease 41 （4.0％） 39 （7.8％） 0.002
　Dementia 13 （1.3％） 11 （2.2％） 0.19
　Neuromuscular disease 10 （1.0％） 12 （2.4％） 0.04
　Post upper digestive system surgery 29 （2.8％） 18 （3.6％） 0.43
　Chronic liver disease 25 （2.4％） 12 （2.4％） 1.00
　Connective tissue disease 41 （4.0％） 15 （3.0％） 0.39
　Mental disorder 10 （1.0％） 4 （0.8％） 1.00
　Malignancy 19 （1.8％） 9 （1.8％） 1.00
　Steroid or immunosuppressant 61（5.9％） 57 （11.4％） ＜0.001
　Alcoholism 5 （0.5％） 4 （0.8％） 0.49
　Others 75 （7.3％） 36 （7.2％） 1.00
Severity, severe 133 （12.9％） 93 （18.6％） 0.004
Treatment effect of initial antibiotics
　2 or more antibiotics 651 （63.1％） 296 （59.2％） 0.15
　Antipseudomonal drug, yes 293 （28.4％） 193 （38.6％） ＜0.001
　Guideline adherence, discordant 348 （33.7％） 196 （39.2％） 0.04
　Failure 130 （12.6％） 97 （19.4％） ＜0.001
Mortality 32 （3.1％） 47 （9.4％） ＜0.001
CAP, community-acquired pneumonia ; HCAP, healthcare-associated pneumonia.
Values are n （％）, unless otherwise indicated ; ＊mean ± standard deviation.
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Table 3.　Diagnostic methods and results
Method
No. of episodes 
studied
No. of positive 
diagnostic studies （％）
Paired sera 286 33 （11.5）
Rapid inuenza diagnostic test 481 37 （7.7）
Urinary antigen （Legionella pneumophila, Streptococcus pneumoniae） 431 100 （23.2）
Culture
　Sputum 435 103 （23.7）
　Transbronchial aspirate 13 3 （21.4）
　Protected specimen brush 1 1 （100.0）
　Bronchial washing 1 1 （100.0）
　Bronchoalveolar lavage uid 11 2 （18.2）
　Blood 299 6 （2.0）
　Pleural uid 3 2 （66.7）
Table 4.　Etiology of healthcare-associated pneumonia
CAP HCAP
Total （n＝1032） Total （n＝500） Severe （n＝93） Non-survivors （n＝47）
Etiology n （％） n （％） P-value n （％） n （％）
Streptococcus pneumoniae 244 （23.6） 108 （21.6） 0.40 20 （21.5） 8 （17.0）
Inuenza virus 96 （9.3） 47 （9.4） 1.00 13 （14.0） 6 （12.8）
Pseudomonas aeruginosa 32 （3.1） 40 （8.0） ＜0.001 9 （9.7） 8 （17.0）
Haemophilus inuenzae 45 （4.4） 23 （4.6） 0.90 4 （4.3） 0 （0.0）
GNEB 28 （2.7） 23 （4.6） 0.07 5 （5.4） 2 （4.3）
　ESBL-producing 28 （2.7） 3 （0.6） - 1 （1.1） 0 （0.0）
　ESBL-nonproducing 0 （0.0） 20 （4.0） - 4 （4.3） 2 （4.3）
Moraxella catarrhalis 10 （1.0） 8 （1.6） 0.32 2 （2.2） 1 （2.1）
Stenotrophomonas maltophilia 0 （0.0） 2 （0.4） 0.11 1 （1.1） 0 （0.0）
Acinetobacter sp. 1 （0.1） 1 （0.2） 0.55 0 （0.0） 0 （0.0）
MRSA 8 （0.8） 4 （0.8） 1.00 4 （4.3） 3 （6.4）
MSSA 3 （0.3） 4 （0.8） 0.23 1 （1.1） 0 （0.0）
Streptococcus sp.* 9 （0.9） 3 （0.6） 0.76 2 （2.2） 1 （2.1）
Atypical pathogen 191 （18.5） 45 （9.0） ＜0.001 9 （9.7） 4 （8.5）
　Legionella spp. 53 （5.1） 18 （3.6） 0.20 6 （6.5） 3 （6.4）
　Mycoplasma pneumoniae 105 （10.2） 16 （3.2） ＜0.001 2 （2.2） 1 （2.1）
　Chlamydia psittaci 15 （1.5） 1 （0.2） 0.03 0 （0.0） 0 （0.0）
　Chlamydia pneumoniae 22 （2.1） 10 （2.0） 1.00 1 （1.1） 0 （0.0）
Others 13 （1.3） 1 （0.2） 0.045 0 （0.0） 0 （0.0）
CAP, community-acquired pneumonia ; ESBL, extended spectrum β-lactamase ; GNEB, Gram-negative enteric bacilli ; 
HCAP, healthcare-associated pneumonia ; MRSA, methicillin-resistant Staphylococcus aureus ; MSSA, methicillin-
sensitive Staphylococcus aureus.
* Indicates other than Streptococcus pneumoniae.
Takashi ISHIGURO, et al268
（Table 5）.  Among these 47 patients, only 8 had received inuenza vaccination.
　There were no differences in the rates of etiology of single pathogens, polymicrobial infections, 
and unknown pathogens between CAP and HCAP patients （P＝0.29）.  MDR pathogens and 
atypical pathogens were found in 9.8％ and 9.0％ of patients, respectively.  The frequency of 
MDR pathogens differed between HCAP and CAP （HCAP, 9.0％ versus CAP, 3.4％）, and atypi-
cal pathogens were more frequent in CAP than HCAP.
Etiology of severe HCAP
　In the 93 patients with severe HCAP, the three most frequently isolated pathogens were S. 
pneumoniae, influenza virus, and P. aeruginosa.  MDR pathogens and atypical pathogens were 
found in 15.1％ and 9.7％ of patients, respectively, and polymicrobial infections occurred in 
15.1％ of patients.  In 10 of 13 patients with influenza virus infection, the virus was detected 
by RIDTs ; paired sera could only be obtained in 6 patients and increased antibody titers were 
found in 4 patients.
Table 5.　Pathogens causing polymicrobial infections
Pathogens Total （n） Severe （n） Non-survivors （n）
2 pathogens
　Streptococcus pneumoniae＋ inuenza virus 7 0 1
　S. pneumoniae＋Haemophilus inuenzae 5 2 0
　S. pneumoniae＋Chlamydophila pneumoniae 1 0 0
　S. pneumoniae＋Legionella spp. 1 0 0
　S. pneumoniae＋Moraxella catarrhalis 2 1 1
　S. pneumoniae＋MRSA 1 1 1
　S. pneumoniae＋GNEB 1 0 0
　Inuenza virus＋Mycoplasma pneumoniae 1 1 1
　Inuenza virus＋MRSA 1 0 0
　Inuenza virus＋H. Inuenzae 2 0 0
　Inuenza virus＋M. catarrhalis 1 0 0
　Inuenza virus＋GNEB 3 2 0
　M. pneumoniae＋Pseudomonas aeruginosa 1 0 0
　P. aeruginosa＋GNEB 3 0 0
　P. aeruginosa＋Legionella spp. 2 1 1
　P. aeruginosa＋MRSA 1 1 1
　M. catarrhalis＋H. inuenzae 1 0 0
　MRSA＋S. maltophilia 1 1 0
3 pathogens
　S. pneumoniae＋ inuenza virus＋Legionella spp. 1 0 0
　S. pneumoniae＋C. pneumoniae＋M. catarrhalis 1 1 0
　S. pneumonia＋ inuenza virus＋M. pneumoniae 1 0 0
　P. aeruginosa＋GNEB＋C. pneumoniae 1 0 0
　P. aeruginosa＋ inuenza virus＋Acinetobacter calcoaceticus 1 0 0
GNEB, Gram-negative enteric bacilli ; MRSA, methicillin-resistant Staphylococcus aureus.
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Initial antibiotic treatment after admission
　Of the 500 patients with HCAP, 296 （59.2％） received two or three antibiotics.  An antip-
seudomonal drug was administered as initial antibiotic therapy in 38.6％ of patients, and none 
received an anti-MRSA agent.  Thus, according to the ATS / IDSA guidelines for HCAP, therapy 
was discordant in all patients 1）.  In contrast, therapy concordant with CAP guidelines was admin-
istered to 304 of the HCAP patients （61.0％） （β-lactams plus macrolides, n＝258 ; plus tetracy-
clines, n＝10 ; uoroquinolones with / without β-lactams and macrolides, n＝36）, while it was not 
administered to 196 patients （β-lactams only, n＝184 ; macrolides only, n＝6 ; tetracyclines only, 
n＝2 ; β-lactams plus clindamycin, n＝4）.
Neuraminidase inhibitors for inuenza virus infection
　Neuraminidase inhibitors （NIs） were administered to 33 of 47 patients （70.2％） with inuenza 
virus infection, based on positive RIDT results in 30 patients and clinical ndings with a nega-
tive RIDT result in 3 patients.  Fourteen of the 30 patients received NIs within 48 h after onset 
based on RIDT results, whereas 3 patients received NIs within 48 h after onset based on clinical 
ndings.
Outcomes
　Treatment with initial antibiotics failed in 97 patients （19.4％）.  Of these 97 patients, 29 
（29.9％） received appropriate antibiotics.  Overall, 47 HCAP patients （9.4％） died.  Among 
the 49 patients with MDR pathogen infections, treatment failure with initial antibiotics occurred 
in 18 patients （P. aeruginosa, n＝14 ; MRSA, n＝1 ; extended-spectrum β-lactamase-producing 
Gram-negative enteric bacilli, n＝1 ; MRSA＋S. maltophilia, n＝1 ; MRSA＋P. aeruginosa, n＝
1）.  Among these 18 patients, 10 patients died, of whom 5 had received appropriate antibiotics. 
Mortality from HCAP was higher than that from CAP.  The most frequently isolated pathogens 
in non-survivors were S. pneumoniae, P. aeruginosa, and influenza virus.  MDR pathogens and 
atypical pathogens were found in 23.4％ and 8.5％ of non-survivors, respectively, and polymicrobi-
al infection occurred in 12.8％ of non-survivors.  All 6 cases of inuenza virus infection in non-
survivors were detected by RIDT, but paired sera could only be obtained in 2 cases.  Among 
the 6 non-survivors with inuenza virus infection, 5 had not received inuenza vaccination, 2 had 
not received NIs, and the remainder had received NIs 48 h or more after onset （Table 6）.
Risk factors for mortality
　Multivariate analysis revealed disease severity and failure of initial antibiotic therapy as inde-
pendent risk factors for mortality （Table 7）.  CAP therapy was not associated with improved 
mortality by univariate analysis.  Congestive heart failure, MRSA infection, and MDR pathogen 
infection were signicant factors by univariate analysis but were nonsignicant factors by multi-
variate analysis.  Infection with S. pneumoniae （odds ratio, 0.725 ; 95％ CI, 0.283-1.639 ; P＝0.55）, 
P. aeruginosa （odds ratio, 2.691 ; 95％ CI, 1.001-6.508 ; P＝ 0.05）, and inuenza virus （odds ratio, 
1.469 ; 95％ CI, 0.481-3.774 ; P＝ 0.54） were not signicant factors by univariate analysis.
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Discussion
　We found that patients with HCAP and CAP differed in demographics, disease etiology and 
severity, and mortality.  In the patients with HCAP, the most frequent microbial agents were S. 
pneumoniae, P. aeruginosa, and inuenza virus.  Severity on admission and treatment failure of 
initial antibiotics were independent risk factors for mortality.
　S. aureus is reported to be the most frequent pathogen （46.7％） of HCAP, followed by P. 
aeruginosa （25.3％）, Klebsiella pneumoniae （7.6％）, and others 2）.  However, only culture-positive 
cases were analyzed.  In the present study, urinary antigen tests, serological analysis, and RIDT 
Table 6.　Characteristics of patients with inuenza virus infection （n＝ 47）
n （％）
Age （y）* 73.3 ± 9.9
Sex （male） 36 （76.6）
Smoking habit 32 （68.1）
Vaccination status
　Yes  8 （17.0）
　Unknown 13 （27.7）
Polymicrobial infection 18 （38.3）
Comorbidity
　No  8 （17.0）
　Respiratory disease alone 15 （31.9）
　Systemic disease alone 10 （21.3）
　Both 14 （29.8）
Severity, severe 13 （27.7）
Neuraminidase inhibitor administration 33 （70.2）
　Within 48 h 17 （36.2）
Non-survivors  6 （12.8）
* Mean ± standard deviation
Table 7.　Univariate and multivariate analysis of the risk of 30-day mortality in the study patients
Univariate analysis Multivariate analysis （final model）
Factor n
Non-
survivors
OR 95％ CI P-value OR 95％ CI P-value
Congestive heart failure 40 9 3.213 （1.252, 7.576） 0.02
Staphylococcus aureus （MRSA） 4 3 30.325 （2.379, 1621.079） 0.006
MDR pathogen 45 10 3.217 （1.314, 7.321） 0.01
Severity, severe 93 27 7.866 （3.995, 15.742） ＜0.001 4.714 （2.230, 9.965） ＜0.001
Treatment effect, failure 97 39 32.797 （14.230, 85.401） ＜0.001 25.734（11.235, 58.943） ＜0.001
CI, condence interval ; MDR, multiple drug-resistant ; MRSA, methicillin-resistant S. aureus ; OR, odds ratio.
Values represent P-value for category against the reference. Values in brackets represent the value for the explana-
tory variable.
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were also used in the etiological diagnosis, with cases of unknown etiology also included.  More 
recent studies have revealed that the most frequent pathogen is S. pneumoniae, and atypi-
cal pathogens have been detected in 0.7％ to 16.1％ of cases 3, 4, 9-12）.  In the present study, S. 
pneumoniae was the most frequent pathogen of HCAP, and the frequency of atypical pathogens 
was 9.0％, results compatible with those of previous reports 3, 4, 9-12）.  Although the frequency of 
atypical pathogens was lower in HCAP than in CAP, the 9.0％ incidence of atypical pathogens 
should not be ignored.  The third leading pathogen was P. aeruginosa, indicating it to be cer-
tainly a major pathogen of HCAP.
　We adopted RIDT and serological analysis to detect influenza virus infection as reported 
previously 5）.  Previous studies have relied on the measurement of antibodies in paired serum 
samples, detection of viral antigen in both lower and upper respiratory tract samples 7, 13-17）, and 
viral culture for diagnosis of viral pneumonia.  Therefore, we included influenza virus in the 
etiology of HCAP according to these reports.  However, it is important to mention the method-
ology of relying on testing of nasopharyngeal specimens for diagnosis of viral pneumonia because 
a virus detected in the nasopharynx may simply represent the presence of an upper respiratory 
infection or pneumonia antigen.
　To our knowledge, there are only 4 reports 4, 10, 18, 19） which investigated influenza virus in 
HCAP.  Carratalà et al 4） reported that influenza virus was detected in only 1 of 126 HCAP 
patients by serology, and Giannella et al 10） found influenza virus infection in 1 of 65 HCAP 
patients by RIDT and serology.  However, a prospective study of Japanese nursing home resi-
dents reported detection of influenza virus in 14.7％ of 75 cases by serology 11）, and influenza 
virus accounted for 9.0％ of our cases.  These results suggest that inuenza virus infection is not 
uncommon in HCAP, which may also be important information for infection control.
　To our knowledge, only one report has described the etiology of severe HCAP 19）.  That report 
introduced the polymerase chain reaction （PCR） method for etiological diagnosis and showed 
that S. pneumoniae and S. aureus （including MRSA） were the most frequent pathogens, followed 
by Gram-negative enteric bacilli and P. aeruginosa.  Inuenza virus infection accounted for 4.5％ 
of pathogens, slightly lower than our results but suggesting that inuenza virus infection is also 
not uncommon in severe HCAP.  RIDT detected most of the cases of influenza virus infec-
tion in the patients with severe HCAP, whereas paired sera could only be obtained in 6 of 13 
patients, indicating that when the diagnosis of inuenza virus infection is based only on paired 
sera, cases with an acute clinical course or early death can be missed.
　In the present study, disease severity was found to be an independent risk factor for mortality 
from HCAP.  The three most widely studied criteria for severe pneumonia are the 20-variable 
Pneumonia Severity Index 20）, the 5-variable CURB-65 score （the score is an acronym for each 
of the risk factors : Confusion, Urea＞ 7 mmol / L, Respiratory rate ≥ 30 / min, low blood pressure, 
and Age ≥ 65）21）, and the 8-variable IDSA / ATS criteria 6）.  We analyzed this study in accordance 
with the 8-variable IDSA / ATS criteria 6）, which is reported to have similar prognostic power to 
the Pneumonia Severity Index 20） in HCAP patients 22）, and disease severity on admission was 
identied as a prognostic factor for mortality from HCAP, as previously reported 23）.
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　We also found treatment failure of initial antibiotics to be associated with mortality.  As 
addressed previously in the guidelines 1）, several factors relate to failure to improve, which include 
bacterial, host, and therapeutic factors.  Because MDR pathogens are more common in HCAP 
than CAP and inappropriate initial antimicrobial therapy increases mortality24, 25）, broad-spectrum 
coverage as empirical therapy has been recommended 1）.  In the present study, the frequency 
of MDR pathogen infections was 9.8％, which was higher than that of CAP in our hospital 5）, 
indicating that patients requiring broad-spectrum therapy more frequently have HCAP than CAP. 
Further, MDR pathogens accounted for 21.3％ of non-survivors, which suggests MDR pathogens 
to be important therapeutic targets to mitigate negative outcomes of HCAP.  Falcone et al 26） 
showed that empirical broad-spectrum therapy was associated with improved outcome in patients 
with HCAP.  However, Attridge et al 27） reported that guideline-concordant HCAP therapy is not 
associated with improved survival compared with guideline-concordant CAP therapy, in nonsevere 
HCAP.  This result may be due to the high prevalence of culture-negative infections, which can 
be treated effectively following a CAP regimen 28, 29）, or to a low local prevalence of resistant 
pathogens 30）.  Unfortunately, because none of our patients had received anti-MRSA therapy, we 
could not assess the relation between HCAP guideline-concordant therapy 1） and outcome.  In 
addition, we found that there were still signicant numbers of traditional CAP pathogens isolated 
in HCAP patients, as reported previously 31, 32）; however, we could not statistically prove the 
efficacy of CAP treatment on mortality in HCAP.  Further studies are needed to determine 
appropriate antibiotic selection.
　Early use of NIs can reduce development of complications such as pneumonia33）, and current 
Center for Disease Control guidelines recommend NIs for hospitalized patients with influenza 
virus infection 34）.  We could not study the efcacy of NIs on inuenza virus infection because 
of the small number of patients, and further studies are needed to clarify this matter in HCAP. 
In addition, Rosón et al 24） reported that factors other than inappropriate antibiotic selection 
are frequent causes of treatment failure and suggested that the capacity of antibiotic therapy to 
further reduce mortality may be limited 24）.  In our study, 29.9％ of patients with disease progres-
sion after initial antibiotic therapy had received appropriate therapy, and 5 of 10 non-survivors 
with MDR pathogen infection had received appropriate therapy.  Similar studies have also been 
reported 35, 36）, and these ndings suggest that treatment strategies for HCAP other than antibiotic 
selection are also required.  HCAP patients are often functionally disabled, and patient-related 
factors including functional status may be needed in the analysis of prognostic factors, which was 
difcult in the present study due to its retrospective nature.
　We analyzed patients meeting the current HCAP criteria 1）.  Because the risk of infection by 
an MDR pathogen is not equivalent for each criterion dening HCAP 9）, the frequency of MDR 
pathogens may differ in accordance with the frequency of patients with each criterion.  Differ-
ences in epidemiology of drug-resistant pathogens and healthcare and social health insurance 
systems among countries and regions should be taken into account.  Park et al 9） reported a poor 
prediction of potentially drug-resistant pathogens in Korea, using the current HCAP criteria.  In 
2011, the Japanese Respiratory Society proposed a modied concept of HCAP called “nursing 
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and healthcare-associated pneumonia”, considering the epidemiological and social environmental 
situations in Japan 37）.  Ishida et al 38） revealed the usefulness of the guidelines in a prospective 
manner.  To dene better strategies and to mitigate negative outcomes from HCAP, further stud-
ies are needed to identify predictive factors of MDR pathogens and prognostic factors.
　The present study has several limitations.  First, because it is a retrospective, observational, 
single-center study, the level of condence is reduced, and the results may not be applicable in 
other settings.  Second, a complete diagnostic workup to determine etiology was not possible in 
every patient.  Third, we did not use PCR assay methods in the etiological diagnosis.  Although 
PCR techniques are more labor intensive and technically demanding and require specialized 
laboratory equipment, PCR is sensitive, and some cases of inuenza or other virus, infection may 
have been missed.
　In conclusion, in the patients with HCAP, the most frequent microbial agents were S. pneu-
moniae, P. aeruginosa, and inuenza virus.  Disease severity and treatment failure of initial anti-
biotics were independent risk factors for mortality from HCAP.  MDR pathogens are important 
therapeutic targets to mitigate negative results, and treatment strategies other than antibiotic 
selection are also required to reduce treatment failure.
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